CClinicalTrials.gg
CompletedNCT02374476Updated Nov 1, 2022Results posted

Bipolar Ventricular Tachycardia (VT) Study

An interventional study of Bipolar Ablation in Ventricular Tachycardia, sponsored by Srinivas Dukkipati. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by Srinivas Dukkipati · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
145
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This non-randomized study will examine the safety and efficacy of irrigated bipolar radiofrequency (RF) ablation in the treatment of ventricular tachycardia (VT) in patients for whom standard VT unipolar RF ablation has been unsuccessful. VT is a serious abnormality of the heart's electrical system. Ablation is a procedure that cauterizes heart tissue using catheters (long tubes that can be moved within or along the outside of the heart). Cauterizing the heart tissue is accomplished by using heat to damage the abnormal heart tissue that is not working well so that it can stop affecting the rest of the heart. Usually, heat is delivered using a unipolar catheter, in which energy travels from the catheter tip to a grounding pad. This research study seeks to find out if a bipolar ablation catheter, in which the energy travels between two catheter tips on either side of the heart muscle, can be used to eliminate the arrhythmia when the unipolar ablation is unsuccessful. The hypothesis is that the increased current density and improved rates of transmural lesion creation seen with bipolar RF ablation will lead to successful arrhythmia termination with minimal or no increased risk of complication.

Read the detailed description

STUDY OBJECTIVE This study will examine the role of irrigated bipolar radiofrequency (RF) ablation for the treatment of intramural ventricular tachycardia in patients who have failed standard unipolar RF ablation. The hypothesis is that the increased current density and improved rates of transmural lesion creation seen with bipolar RF ablation will lead to successful arrhythmia termination with minimal or no increased risk of complication.

INTRODUCTION, RATIONALE Radiofrequency (RF) ablation is the most commonly employed method for the catheter treatment of cardiac arrhythmias. Myocardial scar serves as the most frequent substrate for the genesis of both atrial and ventricular arrhythmia. Such scar frequently contains surviving myocyte bundles interspersed with fibrotic tissue, which leads to slow conduction. Areas of denser fibrosis cause conduction block. When appropriately arranged, conduction through or around these scars leads to the creation of a "reentry" circuit through which an arrhythmia is generated and maintained. Each reentry circuit contains within it an area called the isthmus, a portion of the circuit located in a position intimately related to the scar border zone. Electrical activation travels slowly through the isthmus before breaking out into normal myocardium. Ablation at the site of an isthmus will terminate a reentrant tachycardia.

A variety of techniques, including electroanatomic mapping and activation, entrainment, and substrate mapping, are employed during electrophysiologic (EP) study to identify areas of myocardial scar and potential isthmus sites. Points or lines of ablation using RF energy are then created in an attempt to interrupt the reentry circuit. Typically, unipolar RF energy is applied via a catheter tip electrode to the endocardial or epicardial surface of the heart and grounded via an electrode pad placed on the patient's skin. RF energy in this setting is dispersed through the entirety of the tissue between catheter tip and grounding pad. The standard 7-French, 4-mm tip catheters are highly successful at ablating circuits located within a few millimeters of the catheter tip. A focal, 1mm area of resistive heating occurs within the myocardium immediately in contact with the catheter tip; myocardial cell death occurs several millimeters more deeply through passive, conductive heating, which spreads outward from the contact point.

While the standard catheter is effective at the ablation of superficial arrhythmias, it has proven more problematic when used for deep myocardial sites or for creating transmural lesions. A number of alternatives have been developed in an attempt to access these sites. 8-mm or 10-mm catheter tips are able to create larger zones of resistive heating, delivering direct RF energy to a larger area of myocardium. A larger interface between catheter tip and blood improves cooling and allows for the delivery of more power without a rise in impedence. The clinical use of these larger catheters can, however, be limited by rapid temperature rises at the catheter-tissue interface, resulting in thrombus formation, char, and "steam pop" rupture of the endocardial surface. The use of irrigated ablation catheters have improved upon the ability to deliver RF energy without a sustained rise in impedance. Both open irrigated- and closed-loop irrigated catheters circulate saline along the catheter tip-myocardial interface, allowing for continued delivery of RF current without thrombus formation at the endocardial surface. Intramyocardial temperature rises accordingly without a concomitant endocardial temperature surge, creating larger and deeper myocardial ablation zones. Catheters featuring a retractable needle tipped electrode with intramyocardial saline infusion have also shown promise as a means of accessing deep myocardial circuits in ventricular tachycardia ablation, but are not currently available in the US. Transcoronary ethanol ablation has also been employed with moderate success in patients with arrhythmias resistant to endocardial catheter ablation. This technology, however, grants only limited control over the size of the resulting infarct and is restricted by the need for perfusion of the scar zone by an accessible coronary artery.

Nevertheless, there remain occasions in which an arrhythmia cannot be eliminated by standard unipolar ablation technique. This is seen most frequently due to deep intramural ventricular tachycardia, sometimes encountered following myocardial infarction. Both standard and alternative ablation strategies are frequently either unavailable or inadequate for termination of these arrhythmias.

Recently, several centers have employed irrigated bipolar ablation (BA) to target arrhythmias not amenable to unipolar ablation. During BA, two catheters are connected to either pole of an RF generator, allowing either catheter to function as the "active" catheter and the other the "return" catheter. Rather than being dispersed between the catheter tip and a distant grounding pad, BA concentrates energy between two catheter tips positioned on opposing sides of a target scar. BA may thus improve lesion transmurality through synergistic, simultaneous heating and increased current density leading to concentrated thermal injury.

Initial experience in the use of BA technology in mammalian hearts demonstrated that it could successfully be applied to create discrete areas of myocardial necrosis with minimal risk of complication. When compared to unipolar ablation, several studies suggested that BA could create larger areas of necrosis and transmural lesions with only rare episodes of perforation. Subsequent experience in human hearts was predominantly surgical: a large number of observational studies and reviews demonstrated the effectiveness and safety of BA in patients undergoing pulmonary vein isolation and Cox-Maze surgery as either isolated procedures or as adjuncts to valve replacement or coronary artery bypass surgery.

Despite its broad use during surgical ablation, the application of BA during catheter-based therapies is limited. Recently, our group demonstrated the utility of BA in both an in vitro model and in a series of patients with arrhythmia resistant to unipolar ablation. When compared to unipolar RF ablation, BA was found to be more likely to achieve transmural lesions in a porcine heart model (33% vs 82%, respectively, p = 0.001) and could do so in tissue up to 25 mm thickness. Clinically, all septal atrial flutters, 5 of 6 septal VTs, and 2 of 4 free-wall VTs were successfully acutely terminated.

The proposed study will further examine the role of BA in patients with ventricular tachycardia resistant to standard ablation techniques.

02

Conditions studied

  • Ventricular Tachycardia

Keywords

  • VT
  • Refractory VT
  • VT Storm
  • Ventricular Fibrillation
  • V Fib
  • VF
03

In context

Tachycardia

623 studies on the registry are indexed under Tachycardia; 81 are open to participants now.

This study's enrollment of 145 is above the median of 64 across 379 interventional studies indexed under Tachycardia.

Browse Tachycardia studies →

Lead sponsor

This is the only study on the registry with Srinivas Dukkipati as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ≥ 18 years of age.
  • The study will include all forms of scar VT--both ischemic (post-myocardial infarction) and non-ischemic (eg sarcoid, amyloid, dilated)--as determined by cardiac MRI and/or voltage mapping at the time of VT ablation.
  • Intramural VT not terminable with unipolar ablation once enrolled in the Bipolar study or previous failed unipolar ablation within 6 months prior to enrollment.
  • Ability to understand the requirements of the study and sign the informed consent form.
  • Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements
  • Projected lifespan greater than 1 year.

Exclusion criteria

Exclusion Criteria:

  • Tissue Thickness less than 5 mm as assessed by electroanatomic mapping, CT, or MRI.
  • MI or CABG within 6 weeks.
  • NYHA Class IV CHF.
  • Women known to be pregnant or to have positive beta-HCG.
  • Participation in another study that would interfere with this study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Bipolar Ablation

    All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.

    Device: Bipolar Ablation

  • Active comparator
    Registry

    Participants in Patient Registry after standard radiofrequency (VT) unipolar radiofrequency (RF) ablation was successful

    Device: Bipolar Ablation

Interventions

  • DeviceBipolar Ablation

    Patients will undergo bipolar ablation if unipolar ablation unsuccessful

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT)

    Freedom from recurrent VT at 6 months, defined as sustained ventricular tachycardia lasting longer than 30 seconds and identified due to clinical symptoms or during device interrogation.

    Time frame: 6 months

Secondary outcomes

  1. Number of Procedural Complications

    Total number of procedural complications which includes death, stroke, MI, heart failure, conduction abnormalities, pericardial effusion requiring drainage, hematoma, pseudoaneurysm

    Time frame: 6 months

  2. Number of Participants With Post-ablation Inducibility of VT

    Number of participants to indicate incidence of the induction of any sustained arrhythmia post-ablation, with a duration \> 15 seconds of monomorphic VT (MMVT). Post ablation inducibility is measured via program stimulation.

    Time frame: 6 months

  3. Time to Arrhythmia Termination for the Bipolar Group Only

    When bipolar ablation is performed during ongoing Ventricular Tachycardia (VT), the time to termination is the amount of ablation time that was necessary to cause VT to stop (terminate)

    Time frame: through termination, up to 60 seconds

  4. Total Duration of Bipolar Ablation

    Duration of bipolar ablation is the total procedure time

    Time frame: average of 345 minutes

  5. Number of of Participants With Mortality

    Number of participant from all cause mortality

    Time frame: 6 months

07

Results

Posted Nov 1, 2022

Participant flow

VT Induced Ablation
Participant flow — VT Induced Ablation
MilestoneAll PatientsBipolar AblationRegistry
Started14500
Completed10900
Not completed3600
Withdrew: Screening failures3600
Arm Assignment
Participant flow — Arm Assignment
MilestoneAll PatientsBipolar AblationRegistry
Started04960
Completed04959
Not completed001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryNumber of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT)

Freedom from recurrent VT at 6 months, defined as sustained ventricular tachycardia lasting longer than 30 seconds and identified due to clinical symptoms or during device interrogation.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT)
ParticipantsBipolar AblationPatient Registry
Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT)1629
SecondaryNumber of Procedural Complications

Total number of procedural complications which includes death, stroke, MI, heart failure, conduction abnormalities, pericardial effusion requiring drainage, hematoma, pseudoaneurysm

Time frame:
6 months
Reported as:
Number · events
Number of Procedural Complications
eventsBipolar AblationPatient Registry
Number of Procedural Complications3119
SecondaryNumber of Participants With Post-ablation Inducibility of VT

Number of participants to indicate incidence of the induction of any sustained arrhythmia post-ablation, with a duration \> 15 seconds of monomorphic VT (MMVT). Post ablation inducibility is measured via program stimulation.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants With Post-ablation Inducibility of VT
ParticipantsBipolar AblationPatient Registry
Number of Participants With Post-ablation Inducibility of VT65
SecondaryTime to Arrhythmia Termination for the Bipolar Group Only

When bipolar ablation is performed during ongoing Ventricular Tachycardia (VT), the time to termination is the amount of ablation time that was necessary to cause VT to stop (terminate)

Time frame:
through termination, up to 60 seconds
Reported as:
Mean · seconds
Time to Arrhythmia Termination for the Bipolar Group Only
secondsBipolar Ablation
Time to Arrhythmia Termination for the Bipolar Group Only14.33 ± 10.29
SecondaryTotal Duration of Bipolar Ablation

Duration of bipolar ablation is the total procedure time

Time frame:
average of 345 minutes
Reported as:
Mean · minutes
Total Duration of Bipolar Ablation
minutesBipolar AblationPatient Registry
Total Duration of Bipolar Ablation342.22 ± 133.82317.33 ± 128.98
SecondaryNumber of of Participants With Mortality

Number of participant from all cause mortality

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of of Participants With Mortality
ParticipantsBipolar AblationPatient Registry
Number of of Participants With Mortality95

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bipolar Ablation9/49 (18.4%)26/49 (53.1%)14/49 (28.6%)
Patient Registry5/60 (8.3%)25/60 (41.7%)8/60 (13.3%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventBipolar AblationPatient Registry
Recurrent Ventricular TachycardiaCardiac disorders9/4910/60
Pericardial EffusionCardiac disorders6/491/60
Cardiac TamponadeCardiac disorders4/490/60
Pulmonary Embolism PneumoniaRespiratory, thoracic and mediastinal disorders3/490/60
Congestive Heart FailureCardiac disorders1/493/60
Hemorrhagic ShockCardiac disorders2/490/60
New Incessant Ventricular TachycardiaCardiac disorders2/490/60
PericarditisCardiac disorders2/490/60
Chest pain/FeverGeneral disorders2/490/60
Gastrointestinal HemorrhageGastrointestinal disorders2/490/60
Most frequent other events
Most frequent other events
EventBipolar AblationPatient Registry
Complete Heart BlockCardiac disorders6/492/60
Volume OverloadCardiac disorders3/492/60
Acute Kidney InjuryRenal and urinary disorders2/493/60
Groin HematomaVascular disorders1/491/60
Urinary Tract InfectionInfections and infestations1/490/60
Post Ablation HypotensionVascular disorders1/490/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bipolar AblationPatient RegistryTotal
Mean62.88 ± 11.2963.1 ± 11.3163 ± 11.24
Sex: Female, Male
Sex: Female, Male(Participants)Bipolar AblationPatient RegistryTotal
Female268
Male4754101
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Bipolar AblationPatient RegistryTotal
Count of participants——0
08

Study locations

6 sites
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Brigham & Womans Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Texas Cardiac Arrhythmia Research Foundation
    Austin, Texas 78705, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Aug 24, 2016

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02374476
Lead sponsor
Srinivas Dukkipati
Collaborators
Biosense Webster, Inc.
Responsible party
Srinivas Dukkipati (Co-Director EP Service, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Feb 27, 2015
Start date
Feb 18, 2015
Primary completion
Apr 1, 2020
Completion
Sep 30, 2020
Results posted
Nov 1, 2022
Last update
Nov 1, 2022

Study contacts

Srinivas Dukkipati, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion